Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable gastric / gastroesophageal junction adenocarcinoma
 
This Around the Practice program brings together a multidisciplinary panel to examine evolving perioperative strategies for resectable gastroesophageal and gastric cancers, with a particular focus on integrating systemic therapy, immunotherapy, and surgical planning. Panelists review emerging data from key studies, including the DFLOT regimen evaluated in the MATTERHORN trial, and discuss how these findings may influence real world care once regulatory decisions are finalized. Throughout the program, the experts highlight the importance of accurate staging, appropriate patient selection, and careful assessment of treatment tolerance when approaching complex early stage disease. The discussion incorporates practical considerations faced in both academic and community settings, including nutrition support, feeding access, performance status preservation, germline testing, and the coordination required for patients living at a distance from major centers.

Featured Video
 

Do you know when to use surgery and/or systemic treatment when managing neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN)s?
Education Alert
Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions
0.50 CPD
Experts discuss what you need to know to support your NF1-associated PNs patients.

Learn strategies and diagnostic options with patient cases
Education Alert
The Clock Is Ticking: Diagnostic Strategies for Timely Sepsis Intervention
0.50 CME / CE / ABIM MOC
How can you overcome diagnostic uncertainty with rapid tests and evidence-based strategies for timely sepsis care?

Clinical updates and insights across the care continuum.
Education Alert
Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy
0.50 CME / ABIM MOC
Are you regularly testing for TRK fusions in cancers with high fusion frequency?

Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma - Expert Perspectives on AQUILA Phase 3 Trial and FDA Approval
Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements.

Featured Video

Malnutrition Poorly Impacts Survival With CCRT in Advanced Cervical Cancer


Cancer Vaccine Trial Receives FDA IND Clearance in Advanced Melanoma

New Career Center Video:   Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now.
Videos
Trending

Optimizing Hypomethylating Therapy in Myelodysplastic Syndromes
This program focuses on optimizing the use of oral hypomethylating agents (HMAs) in myeloid malignancies, primarily high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). A multidisciplinary panel of hematologists, transplant specialists, and an oncology nurse practitioner discusses real-world cases involving TP53-mutated MDS and proliferative CMML, both complicated by cytopenias, comorbidities, logistical challenges, and patient preferences. Panelists review evidence supporting oral decitabine/cedazuridine as a practical and clinically effective therapy comparable to intravenous HMAs. They also discuss transplant candidacy, timing, and the emerging role of combination therapies such as venetoclax with oral HMAs. Across the program, speakers emphasize individualized patient-centered care, balancing disease control with quality of life, treatment burden, telemedicine integration, and realistic expectations. The experts conclude that oral HMA therapy will lead to broader community-based treatment, greater patient autonomy, and future expansion of combination regimens and clinical trials.

Featured Video
Practical Implementation of Oral HMAs in MDS/CMML: Safety, Monitoring, and Coordination
Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes.

Clinical Essentials
Quick Picks Read By QxMD